Company gets U.S. patent for Alzheimer vaccine.

2003 DEC 10 - (NewsRx.com & NewsRx.net) -- Mindset BioPharmaceuticals (USA), Inc., announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for claims covering the company's vaccine for Alzheimer disease.

The vaccine, invented by scientists at New York University School of Medicine, and exclusively licensed to Mindset for development, elicits a response against the beta-amyloid protein known to be toxic to nerve cells and to form insoluble aggregates that accumulate in the brains of Alzheimer patients.

This vaccine approach is based on soluble, synthetic homologues of the human amyloid toxin, which were found to be highly immunogenic when tested in animals. Also, in relevant animal models of Alzheimer disease, the Mindset vaccine was shown to inhibit the deposition of toxic amyloid fibrils and to improve cognition.

Mindset's technology potentially addresses several major safety concerns for developing a vaccine to beta-amyloid, a protein which is naturally present in the brain ...